This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
With the aim of improving knowledge and care of hereditary cancer in primary health care system, the Spanish National Cancer Research Centre (CNIO) and the Roche Institute have reached a specific collaboration agreement that will serve to implement an ambitious training programme. The agreement, which is included within a broad, well-established framework of understanding between both institutions, will be directed mainly towards familial physicians and primary health care professionals.
As the Managing Director of the Roche Institute, Jaime del Barrio, says: “the final aim is to contribute to improving knowledge and care of hereditary cancer, with special emphasis on those aspects related to cancer prevention and personalised treatment.”
CLOSING A TRAINING GAP
Although over the past few years much progress has been made in our country from a diagnostic and genetic assessment point of view, “the theoretical training in familial cancer is not regulated in the field of biomedicine”, says Javier Benítez, the Director of CNIO’s Human Cancer Genetics Programme, and Head of the Human Genetics Group. In his opinion: “primary care professionals ought be familiarised with new diagnostic technologies and the way in which these technologies offer an effective patient handling.”
The training programme contemplates the use of digital materials which will include 24 areas ok knowledge and will be updated every tree months.
Together with the development of the main subjects, the application will include additional sections providing information on other issues or news related to hereditary cancer. The plan is to also organise courses and meetings in order to offer a broad view, from multiple perspectives, of hereditary cancer with special relevance to the primary health care system.